Therefore, Chinese National Medical Products Administration has approved camrelizumab monotherapy as the second-line treatment and camrelizumab + chemotherapy as the first-line treatment for treating ESCC regardless of the PD-L1 CPS status. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.